Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma

Haematologica

Volumn 96, Issue 6, 2011, Pages 874-880

  Vishwamitra, Deeksha ^a,b   Shi, Ping ^a,c   Wilson, Desiree ^a   Manshouri, Roxsan ^a   Vega, Francisco ^a   Schlette, Ellen J ^a   Amin, Hesham M ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AXL1717; IGF IR; Mantle cell lymphoma; Picropodophyllin; Rituximab

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYTOCHROME C; INSULIN RECEPTOR SUBSTRATE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PODOPHYLLIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TYPE I INSULIN LIKE GROWTH FACTOR RECEPTOR TYROSINE KINASE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MESSENGER RNA; PICROPODOPHYLLIN; PODOPHYLLOTOXIN; PROTEIN KINASE INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA CELL LINE; MALE; MANTLE CELL LYMPHOMA; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; CELL STRAIN K 562; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; K562 CELLS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PODOPHYLLOTOXIN; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 79958042289     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031567     Document Type: Article

References (47)

1. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5(10):2503-12.
2. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002;1(10):769-83.
3. Kato H, Faria TN, Stannard B, Roberts CT Jr, Le Roith D. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol. 1994;8(1): 40-50.
4. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999;19(10):7203-15.
5. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene. 2004;23(47): 7854-62.
6. Zong CS, Chan J, Levy DE, Horvath C, Sadowski HB, Wang LH. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem. 2000;275(20): 15099-105.
7. Gual P, Baron V, Lequoy V, Van Obberghen E. Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor. Endocrinology. 1998;139(3):884-93.
8. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28(1):20-47.
9. Baserga R, Sell C, Porcu P, Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif. 1994;27(2):63-71.
10. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 1993;90(23):11217-21.
11. Toretsky JA, Kalebic T, Blakesley V, Le - Roith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272(49):30822-7.
12. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93(24): 1852-7.
13. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgendependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res. 2005;11(8):3065-74.
14. Iwasa T, Okamoto I, Suzuki M, Hatashita E, Yamada Y, Fukuoka M, et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res. 2009;15 (16):5117-25.
15. Coppola D, Saunders B, Fu L, Mao W, Nicosia SV. The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res. 1999;59(13):3264-70.
16. Wilker E, Bol D, Kiguchi K, Rupp T, Beltrán L, DiGiovanni J. Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor- 1 receptor in the epidermis of transgenic mice. Mol Carcinog. 1999;25(2):122-31.
17. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets. 2009;10(10):923-36.
18. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009;28(34): 3009-21.
19. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1Rmediated growth in hematopoietic cells. Leukemia. 2006;20(7):1254-60.
20. Strömberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006;107(2):669-78.
21. Menu E, Jernberg-Wiklund H, Strömberg T, De Raeve H, Girnita L, Larsson O, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. 2006;107(2):655-60.
22. Shi P, Lai R, Lin Q, Iqbal AS, Young LC, Kwak LW, et al. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood. 2009;114 (2):360-70.
23. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, et al. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. J Cell Mol Med. 2010;14(6B):1777-92.
24. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, et al. The insulinlike growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia. 2007;21(5):886-96.
25. Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, et al. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res. 2009;69(19):7635-43.
26. Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23 (26):6364-9.
27. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750-62.
28. Williams ME, Dreyling MH, Kahl BS, Leonard JP, O'Connor OA, Press OW, et al. Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2010;51(3): 390-8.
29. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, et al. Characterization of 4 mantle cell lymphoma cell lines: establishment of an in vitro study model. Arch Pathol Lab Med. 2003;127(4):424-31.
30. Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspaseindependent mechanism involving the generation of reactive oxygen species. Blood. 2001;98(9):2771-7.
31. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100(5):1765-73.
32. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101 (3):949-54.
33. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood. 2006;108(7):2407-15.
34. Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol. 2007;212(4):402-10.
35. Rosengren L, Vasilcanu D, Vasilcanu R, Fickenscher S, Sehat B, Natalishvili N, et al. IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). Biochem Biophys Res Commun. 2006;347(4):1059-66.
36. Rubini M, Hongo A, D'Ambrosio C, Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res. 1997; 230(2):284-92.
37. Flossmann-Kast BB, Jehle PM, Hoeflich A, Adler G, Lutz MP. Src stimulates insulinlike growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res. 1998;58(16):3551-4.
38. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res. 2007;13(14): 4291-99.
39. Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene. 2001;20 (57):8203-14.
40. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995;55(10): 2007-11.
41. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer. 1999;83(1):15-7.
42. Ekman S, Frödin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small lung carcinoma. Acta Oncol. 2011;50(3): 441-7.
43. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev. 2006;17(4):305-23.
44. Hamelers IH, van Schaik RF, Sipkema J, Sussenbach JS, Steenbergh PH. Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells. J Biol Chem. 2002;277(49):47645-52.
45. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13(9):2124-30.
46. Lovec H, Grzeschiczek A, Kowalski M-B, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13(15):3487-95.
47. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene. 2006;25(7):998-1007.